InvestSMART

Paradigm Biopharmaceuticals Limited (ASX: PAR) - Announcements

Current share price for PAR : $0.265 0.025 (10.42%)+

ASX company news and announcements for Paradigm Biopharmaceuticals Limited (PAR) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Paradigm Biopharmaceuticals Limited (PAR) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Paradigm Biopharmaceuticals Limited (PAR), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Paradigm Biopharmaceuticals Limited (PAR)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$161 Response to ASX Query 21 Jan 2021 5:27PM $2.440 $0.265 fallen by 89.14%
$161 Change in substantial holding 18 Jan 2021 5:50PM $2.450 $0.265 fallen by 89.18%
$161 Change of Director's Interest Notice 18 Jan 2021 5:50PM $2.450 $0.265 fallen by 89.18%
$161 Change of Director's Interest Notice 18 Jan 2021 5:49PM $2.450 $0.265 fallen by 89.18%
$161 39th Annual JP Morgan Healthcare Conference Presentation 12 Jan 2021 5:33PM $2.390 $0.265 fallen by 88.91%
$161 Paradigm to present at the J.P. Morgan Healthcare Conference 6 Jan 2021 8:23AM $2.400 $0.265 fallen by 88.96%
$161 R&D Investor Presentation 21 Dec 2020 9:17AM $2.450 $0.265 fallen by 89.18%
$161 PARADIGM RECEIVES POSTIVE FEEDBACK FROM FDA TYPE C MEETING 18 Dec 2020 8:40AM $2.540 $0.265 fallen by 89.57%
$161 Cleansing Notice and Appendix 2A 17 Dec 2020 4:14PM $2.540 $0.265 fallen by 89.57%
$161 Initial Director's Interest Notice 15 Dec 2020 6:23PM $2.510 $0.265 fallen by 89.44%
$161 Paradigm Provides Phase 3 Clinical Trial Update 14 Dec 2020 8:23AM $2.610 $0.265 fallen by 89.85%
$161 Paradigm welcomes Amos Meltzer as Non-Executive Director 9 Dec 2020 8:20AM $2.840 $0.265 fallen by 90.67%
$161 Paradigm to Host Inaugural R&D Day 8 Dec 2020 8:25AM $2.750 $0.265 fallen by 90.36%
$161 Paradigm to Present at Evercore ISI HealthCONx Conference 1 Dec 2020 12:36PM $3.000 $0.265 fallen by 91.17%
$161 Cleansing Notice and Appendix 3G 25 Nov 2020 4:09PM $2.910 $0.265 fallen by 90.89%
$161 Final Director's Interest Notice 20 Nov 2020 4:40PM $3.020 $0.265 fallen by 91.23%
$161 Resignation of Non-Executive Director 20 Nov 2020 8:14AM $3.050 $0.265 fallen by 91.31%
$161 Results of Meeting 19 Nov 2020 3:23PM $3.050 $0.265 fallen by 91.31%
$161 Paradigm AGM Presentation 19 Nov 2020 10:16AM $3.000 $0.265 fallen by 91.17%
$161 FIRST PATIENT DOSED IN MPS-I PHASE 2 CLINICAL TRIAL 12 Nov 2020 8:19AM $3.080 $0.265 fallen by 91.40%
$161 Ordinary Shares Cancellation 6 Nov 2020 4:24PM $3.000 $0.265 fallen by 91.17%
$161 Paradigm to present at NWR Virtual Conference 4 Nov 2020 8:22AM $2.750 $0.265 fallen by 90.36%
$161 Quarterly Update and Appendix 4C - quarterly 30 Oct 2020 12:50PM $2.700 $0.265 fallen by 90.19%
$161 Notice of Annual General Meeting/Proxy Form 15 Oct 2020 8:18AM $3.080 $0.265 fallen by 91.40%
$161 PARADIGM ADDS MORE TALENTED SENIOR EXECUTIVES TO ITS TEAM 13 Oct 2020 8:15AM $3.000 $0.265 fallen by 91.17%

401 - 425 of 725 results

Page 17 of 29

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.